Karin Schölin Bywall

MSc Public Health
PhD Student

Karin Schölin Bywall is a PhD student in the IMI-funded PREFER project. The project is aiming to investigate methodologies to elicit informed patient preferences regarding the benefits and risks of drugs, from development through the entire cycle, to inform the decision-making process by regulators and HTA bodies.

Karin Schölin Bywall has a master of science in public health from Mälardalen University where she also teached in public health.

E-mail: karin.bywall@crb.uu.se
Phone: +46 18 471 62 49

Recently in the media

Patienters syn på att inkluderas i forskning om läkemedel
Reumatikerförbundet, 2018-12-18

Publications

Janssens, Rosanne; Russo, Selena; van Overbeeke, Eline; Whichello, Chiara et al.

Patient Preferences in the Medical Product Life Cycle: What do Stakeholders Think? Semi-Structured Qualitative Interviews in Europe and the USA

Part of Patient, 2019.

DOI To DiVA

Open access
Schölin Bywall, Karin; Veldwijk, Jorien; Hansson, Mats G.; Kihlbom, Ulrik et al.

Patient Perspectives on the Value of Patient Preference Information in Regulatory Decision Making: A Qualitative Study in Swedish Patients with Rheumatoid Arthritis

Part of Patient, p. 297-305, 2019.

DOI Uploaded full-text To DiVA

Open access
Whichello, Chiara; Schölin Bywall, Karin; Mauer, Jonathan; Watt, Stephen J. et al.

Mapping benefit-risk decision-making processes and identifying decision points with the potential to include patient preference information throughout the medical product lifecycle

Part of Pharmacoepidemiology and Drug Safety, p. 206-206, 2018.

DOI To DiVA

Open access
Janssens, R.; Huys, I; van Overbeeke, E.; Whichello, C. et al.

Stakeholder Perspectives On The Integration Of Patient Preferences In The Medical Product Life Cycle: A Multimethod Approach

Part of Value in Health, p. A689-A689, 2017.

DOI To DiVA
Schölin Bywall, Karin; Veldwijk, Jorien; Hansson, Mats G.; Kihlbom, Ulrik et al.

Rheumatoid Arthritis Patients’ Perspectives On The Value Of Patient Preferences In Regulatory Decision-Making During Drug Development: A Qualitative Study

Part of Value in Health, p. A540-A540, 2017.

DOI To DiVA
van Overbeeke, E.; Whichello, C.; Janssens, R.; de Bekker-Grob, E. et al.

Conditions And Contextual Factors That Influence The Utility And Application Of Patient Preference Studies: A Study Combining Literature And Focus Groups

Part of Value in Health, p. A690-A691, 2017.

DOI To DiVA

Risk information

We are investigating risk information from serval perspectives.

Our research in this field

Patient preferences

Giving patients a voice in drug development

PREFER is a five year public-private research project where academic researchers and the pharmaceutical industry work together to find out when and where patients want, can and should be involved in drug development

Visit the PREFER website

Patient prefrences

Rheumatoid Arthritis

Karin Schölin Bywall will look at how rheumatoid arthritis patient preferences can provide added value in regulatory decision making in the drug development process.

PhD project

Methodology, rheumatoid arthritis and patient involvement

Drugs should benefit patients. By extension, they should have a say in designing research meant to find out what they think about drugs. Here, Karin Schölin Bywall shares her thoughts about involving patients in research and working together with stakeholders.

Read interview

Karin Schölin Bywall